ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY
Mohty, M, Tomasson, M, Arnulf, B, Bahlis, N, Prince, M, Niesvizky, R, Rodrgue-Otero, P, Martine-Lopez, J, Koehne, G, Jethava, Y, Gabayan, A, Stevens, D, Nooka, A, Raje, N, Iida, S, Leip, E, Conte, U, Czibere, A, Viqueira, A, Blunk, V, Lesokhin, A
Published in Hematology, Transfusion and Cell Therapy (01.10.2023)
Published in Hematology, Transfusion and Cell Therapy (01.10.2023)
Get full text
Journal Article